Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

David A. Sallman, MD, Hany Elmariah, MD MS, Kendra L. Sweet, MD MS, Chetasi Talati, MD, Asmita Mishra, MD, Linda L. Kelley, PhD, Amy Lankford, PhD, Tim Chan, PhD, Rutul R Shah, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Helen Sabzevari, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139417

Published: 2020

Journal Articles

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Mohammad O Hussaini, MD, David A. Sallman, MD, Dana Elise Rollison, PhD, Eric Padron, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139710

Published: 2020

Journal Articles

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, PhD, Bin Yu, Gongbo Li, PhD MBBS, Bishwas Shrestha, PhD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ana Marie Landin, Adam William Mailloux, PhD, Claudio Anasetti, MD, Linda L. Kelley, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136174

Published: 2020

Journal Articles

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

David A. Sallman, MD, Tracey Iraca, Casey L. O'Connell, MD, Rafael Bejar, MD PhD, Sandra Kurtin, ANP

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134647

Published: 2020

Journal Articles

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Onyee Chan, MD, Najla Al Ali, MD, David A. Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141960

Published: 2020

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Seongseok Yun, MDPhD, David Gajzer, MD, Najla Al Ali, M.Sc, Nicole D. Vincelette, PhD, Pukhraz Basra, MBBS, Chetasi Talati, MD, Andrew T. Kuykendall, MD, Eric Padron, MD, Kendra Sweet, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137116

Published: 2020

Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138833

Published: 2020

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

Amy Song, Omar Altabbakh, BS, David A. Sallman, MD, Eric Padron, MD, Chetasi Talati, MD, Mohammad O Hussaini, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142615

Published: 2020

Journal Articles

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Gail J. Roboz, MD, Daniel J. DeAngelo, MD PhD, David A. Sallman, MD, Monica L. Guzman, PhD, Pinkal Desai, MDMPH, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Francisco Javier Esteva, MD PhD, Andrew Garton, Kate Backhouse, Roman Galetto, PhD, Carrie Brownstein, MD, Naveen Pemmaraju, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138984

Published: 2020

Journal Articles

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Franco Castillo Tokumori, MD, Chetasi Talati, MD, Najla E. Al Ali, David A. Sallman, MD, Seongseok Yun, MDPhD, Kendra L. Sweet, MD MS, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD, Andrew T. Kuykendall, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-140145

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

Journal Articles

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Anthony M. Hunter, MD, Najla Al Ali, M.Sc, David A Sallman, MD, Kendra L. Sweet, MD, Andrew T Kuykendall, MD, Chetasi Talati, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 1717.

https://doi.org/10.1182/blood-2019-131071

Published: 2019

Journal Articles

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Chetasi Talati, MD, Hannah H Asghari, MD, Jinming Song, MD PhD, Mohammad Hussaini, MD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 2052.

https://doi.org/10.1182/blood-2019-129742

Published: 2019

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Chetasi Talati, MD, Ryan J Caddell, PharmD, BCOP, Katherine Tobon, PharmD, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Eric Padron, MD, Hugo F. Fernandez, MD, Alan F. List, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 2636.

https://doi.org/10.1182/blood-2019-129166

Published: 2019

Journal Articles

Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer

Tim Chan, PhD, Xiaohong Ma, Fernando Carvajal-Borda, DVM, Jose Velez, Jacques Plummer, Lindsey Shepard, Rutul R Shah, David A Sallman, MD, Helen Sabzevari, PhD

Blood (2019) 134 (Supplement_1): 2660.

https://doi.org/10.1182/blood-2019-130617

Published: 2019

NARROW

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only